• Japanese
  • Korean
  • Chinese
Cover Image

Anti-Obesity Drugs

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -

Arena Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Novo Nordisk
Orexigen Therapeutics, Inc.
Rhythm Pharmaceuticals

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Anti-Obesity Therapeutics - A Significantly Underserved Market
  • Obesity: An Unmet Medical Need
  • Currently Available Drugs
  • List of Currently Available Drugs for the Treatment of Obesity
  • The United States - The Largest Obesity and Anti-Obesity Market
  • Europe - A Market with Vast Potential
  • Emerging Economies to Lead Growth
    • Table 1: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart)

2. COMPETITIVE SCENARIO

  • Drug Withdrawals Alter Competition Metrics
  • Unfavorable Reimbursement Levels Hamper Growth
  • New Entrants to Induce Competition
  • Anti-Obesity Drugs Under Pipeline

3. MARKET TRENDS, DRIVERS AND CHALLENGES

  • Alarming Rise in Global Obesity Levels - The Major Growth Factor
    • Table 2: Classification of BMI
    • Table 3: Overweight and Obese Population (Millions) for 2013 in Select Geographic Regions (includes corresponding Graph/Chart)
    • Table 4: Global Obesity Levels by Leading Countries and Others (2013): Percentage Breakdown of Obese Population for the United States, India, China, Mexico, the United Kingdom, Germany, Spain, Australia, Canada, Japan, Greece, South Korea, Portugal, Slovakia, New Zealand, Finland, Switzerland, Ireland, and Others (includes corresponding Graph/Chart)
    • Table 5: Abdominal Obesity Prevalence (%) by Region and Gender (includes corresponding Graph/Chart)
  • Growing Emphasis on Metabolism
  • New Research Aids in Discovery of Novel Drugs
  • Cyclic Guanosine Monophosphate Signaling - The Future of Anti-Obesity Pharmacotherapy?
  • Childhood Obesity - A Market with Unmet Needs
  • Online Drug Stores Boost Sales
  • Barriers to Development of Effective Drugs
  • Regulatory Additions - A Barrier to Entry?
  • High Drug Development Costs - A Major Setback
  • Weight Loss Alternatives - A Market Dampener
  • Short Treatment Duration - A Major Limiting Factor for Market Growth
  • Product Labelling Could Deter Treatment Continuation

4. SELECT PIPELINE DRUG CANDIDATES

  • Orexigen Completes Phase 3 Clinical Trials for NB32
  • Empatic(tm) Completes Phase II
  • Zafgen Completes Phase II Trial of Beloranib
  • Novo Nordisk Completes Phase III trial of Liraglutide
  • Rhythm Pharmaceuticals Commences Phase 2 Trials for RM 493
  • University of Michigan to Commence Trial of Amlexanox in Treating Obesity

5. SELECT SCIENTIFIC BREAKTHROUGHS

  • Study Links PAR2 Protein Amount to Obesity
  • Scientists at Cambridge University Discover Hunger Gene
  • Ghrelin Hormone Linked to Hunger and Obesity

6. OBESITY - AN INTRODUCTION

  • Diagnosis of Obesity
  • BMI Calculation and Classification
  • Waist Circumference and BMI
  • Types of Obesity
  • Monogenic Obesity
  • Polygenic Obesity
  • Causes of Obesity
  • Unhealthy Eating Habits
  • Environmental and Genetic Factors
  • Sedentary Lifestyle
  • Alcohol Intake
  • Childhood Obesity
  • Psychological Factors
  • Pregnancy
  • Hormonal Disorders
  • Drugs
  • Aging
  • Risks Associated with Obesity

7. OBESITY TREATMENT

  • Dietary Therapy
  • Exercise Therapy
  • Behavior Therapy
  • Pharmacotherapy
  • Weight Loss Surgery
  • Invasive Vis-a-vis Non-invasive Procedures
  • A Brief Review of Select Invasive Procedures
  • Bariatric Surgery
  • Laparoscopic Adjustable Gastric Banding (LAGB)
  • Vertical Banded Gastroplasty (VBG)
  • Roux-en-Y Gastric Bypass Procedure (RYGB)
  • Lap-Band Procedure
  • Gastric Band Procedure
  • Gastric Bypass Procedure
  • Doudenal Switch
  • Prescription Drugs Vis-a-vis Non-Prescription Drugs
    • Table 6: Obesity Treatment Options and Corresponding Success Rate

8. ANTI-OBESITY DRUGS - AN INSIGHT

  • Introduction
  • Mechanism of Action
  • Review of Available Prescription Anti-Obesity Drugs
  • Phentermine
  • Orlistat
  • Belviq (Lorcaserin)
  • Phentermine/Topiramate Cocktail
    • Table 7: Global Anti-obesity Prescription Drugs Market (2012): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obstetrics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and Others (includes corresponding Graph/Chart)

9. RECENT INDUSTRY ACTIVITY

  • Novo Nordisk to Launch Anti-Obesity Drug in Mexico
  • Orexigen Optimistic of FDA Approval for Contrave
  • Arena Extends Belviq Distribution Agreement with Eisai
  • Sorrento Partners Scripps Research
  • MedImmune Partners NGM Biopharmaceuticals to Develop Anti-Obesity Therapy
  • Arena Launches Belviq
  • Kitozyme Signs Deal with Corona
  • GSK and Vanderbilt Sign Agreement for New Anti-Obesity Drug
  • ScinoPharm Signs Agreement for Contract Manufacturing
  • Vivus Launches Qsymis
  • ScinoPharm Enters Supply Deal with Vivus

10. FOCUS ON SELECT PLAYERS

  • Arena Pharmaceuticals, Inc. (US)
  • F. HOFFMANN-LA ROCHE LTD. (Switzerland)
  • GlaxoSmithKline Plc. (UK)
  • Novo Nordisk (Denmark)
  • Orexigen Therapeutics, Inc. (US)
  • Rhythm Pharmaceuticals (US)
  • VIVUS, Inc. (US)
  • Zafgen Inc. (US)

11. GLOBAL MARKET PERSPECTIVE

    • Table 8: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 9: World Historic Review for Anti-Obesity Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 10: World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Table 11: US Weight Loss Market by Major Product Segment (2013): Percentage Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs, and Others (includes corresponding Graph/Chart)
    • Competitive Scenario
    • Obesity Catching Them Young
    • Table 12: US Childhood Obesity by Age-Group (2013): Percentage of Obese Population (includes corresponding Graph/Chart)
    • Penetration of Anti-Obesity Drugs Remains Poor
      • Key Statistics
    • Table 13: US Obesity Rates by Ethnicity for Men & Women: 2013 (includes corresponding Graph/Chart)
    • Table 14: Proportion (%) of Obesity in the US Overweight Population by Age Group (includes corresponding Graph/Chart)
    • Table 15: Obesity Prevalence in US Adults by Type (2013) (includes corresponding Graph/Chart)
    • Table 16: US Obesity Prevalence by Age-group: 2013 (includes corresponding Graph/Chart)
    • Table 17: US Obesity Prevalence by Annual Income Level (%): 2013 (includes corresponding Graph/Chart)
      • State-wise Stats
    • Table 18: US Obesity Prevalence by Top Cities (% of Total Population): 2013 (includes corresponding Graph/Chart)
    • Table 19: US Prevalence of Obesity by Top States (% of Total Population): 2013 (includes corresponding Graph/Chart)
    • Reimbursement Scenario
    • Regulatory Environment
      • High Development Costs - A High Entry Barrier for Drug Makers
      • Lack of Overall efficacy and outcomes data - A Dampener
    • Obesity and Related Ailments: Burden on Societal and Economic Costs
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 20: The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 21: The US Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 22: Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 23: Canadian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 24: Japanese Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 25: Japanese Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Europe - an Opportune Market for Chronic Weight Management Drugs
    • Prevalence of Obesity in Europe
    • Table 26: Obese and Overweight & Obese Population in the European Union (2013): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
    • Table 27: Select EU Member Countries Ranked by Obesity Rates (2013): Percentage Share of Domestic Obese Population in Global Obese Population (includes corresponding Graph/Chart)
    • Table 28: Obesity Prevalence in Select EU Countries (2013) by Gender (%) (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 29: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 30: European Historic Review for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 31: European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Changing Lifestyle Alters Health Profile
  • B. Market Analytics
    • Table 32: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: French Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • The Largest Anti-Obesity Market in Europe
  • B. Market Analytics
    • Table 34: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: German Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 36: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 37: Italian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Anti-Obesity Drugs - the Need of the Hour as NHS Firefights Rising Peril of Obesity
    • GlaxoSmithKline Plc - A Key Player
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 38: The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 39: The UK Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Review of Select Markets
      • Spain
      • Belgium
      • The Netherlands
      • Finland
      • Sweden
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 40: Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 41: Rest of European Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Brief Review of Select Countries
      • Australia
    • Table 42: Australian Obesity & Overweight Prevalence (2013): Percentage Share Breakdown of Population for Obese/Overweight, Healthy Weight and Underweight Categories (includes corresponding Graph/Chart)
      • Historic Perspective:
    • Table 43: Prevalence Rate (%) of Overweight/Obese Students in Australia (includes corresponding Graph/Chart)
      • China
      • India
      • Korea
      • Use of Diet Pills Lack Proper Monitoring
      • New Zealand
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 45: Asia-Pacific Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Mexico - A Review
  • B. Market Analytics
    • Table 46: Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 47: Latin American Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
    • Table 48: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 49: Rest of World Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Show More
Pricing
Get Notified
Email me when related reports are published